A Large Parotid Hemangioma Managed Successfully with Propranolol.

The treatment of parotid hemangiomas has posed a challenge. A male infant presented with large hemangioma of the right parotid gland diagnosed at the age of 3 months. Starting at the age of 4 months, he was treated with oral propranolol for 10 months, which led to a marked reduction in tumor size and strawberry hemangioma. Our case shows that propranolol is effective and safe in treating large parotid infantile hemangioma.

Introduction

Parotid hemangiomas represent 0.4–0.6% of the tumors involving the parotid gland, and are more common in children than in adults.1 Most of them are asymptomatic. Previous studies have shown that propranolol shrinks most parotid hemangiomas.2 However, 2–20% of patients with infantile hemangioma may present resistance to propranolol or have contraindications.3

We present a male infant with a large hemangioma of the right parotid gland managed successfully with propranolol.

Case Report

A 3-month-old male, otherwise healthy, presented with a swelling over the right side of his face that was initially noticed at 4 weeks of age. It was rapidly increasing in size. There was no pain, history of trauma, prematurity, or advanced maternal age. Clinical examination revealed a large swelling in the right parotid region which was extending behind the ipsilateral ear lobe. Strawberry hemangioma was noted in the overlying cutaneous tissue. The mass was soft and non-tender (Figure 1A and B). An ultrasound scan showed a large mass in the right parotid gland, which measured 7.1×6.1×6.8 cm. The mass was very vascular with low-resistance arterial and venous components, mainly from the branch of the right carotid artery, and drained into the right jugular vein. Based on the clinical presentation and sonographic parameters, the diagnosis of infantile hemangioma of the right parotid gland was made. Cervical MRI showed a T1-isointense (Figure 2A), T2-hyperintense lesion replacing the whole of the parotid gland (Figure 2B), which was pushing against the digestive tract. Oral propranolol was initiated at 1 mg/kg/day as a single oral dose, after pretreatment evaluation, at the age of 4 months. It was well tolerated by our patient: monitoring of heart rate, respiratory rate, and blood pressure was normal. His propranolol dose was increased to 2 mg/kg/day and weight adjusted at monthly visits without side effects. For the first month, the infant was followed up on a 2-weekly, then at a monthly interval. Significant shrinkage and paleness of the lesion was noted at 4 months. At the 10-month follow-up, there was complete disappearance of the parotid hemangioma (Figure 3A and B).

Figure 1

Large swelling in the anatomic area of the right parotid gland, prior to initiating treatment: (A) right profile; (B) front view.

Figure 2

Magnetic resonance imaging showing (A) T1-isointense and (B) T2-hyperintense lesion replacing the whole of the parotid gland.

Figure 3

Marked reduction of parotid hemangioma after 10 months of oral propranolol: (A) right profile; (B) front view.

Discussion

Hemangioma of the parotid gland is the most common tumor of the salivary glands in childhood; however, it represents only 1–5% of all salivary gland tumors.4

Most hemangiomas of the parotid gland can be diagnosed based on the typical clinical presentation of a mass that is evident after birth and shows rapid growth. As in our case, the diagnosis may be made clinically if the skin overlying the lesion is involved. MRI gives more precision on the size and depth of the tumor and its relationship to adjacent structures.5

The treatment of pediatric infantile hemangioma of the head and neck, and particularly of the parotid gland, is not codified. The size, stage, and location of lesions, presence of ulceration and bleeding, functional obstruction, and risk of deformity are the determinants of the treatment plan. The impressive effect of propranolol in treating infantile hemangiomas changed the principle in their treatment, with several reports being published since 2008.6 In addition, propranolol is well tolerated.

Several authors have reported the effectiveness of propranolol in hemangioma of the parotid gland.7,8 However, Harris and Phillips found that parotid hemangiomas have a lower response rate to propranolol and need a longer treatment course compared to infantile hemangioma at other sites.9

Most infantile hemangiomas complete their proliferative growth phase before 9 months of age. However, some authors have reported a recurrence of hemangioma of the parotid gland when propranolol was discontinued after 9 months of age.9,10 This is why we decided to continue propranolol therapy until 14 months of age. As described in our case, large size and facial location are the most important predictors of poor short-term outcomes.

Our patient’s case shows that propranolol is effective and safe in treating infantile hemangioma of the parotid gland.